Introduction
Diabetic nephropathy (DN) remains the most common cause for end stage renal disease (ESRD) as the burden of diabetes increases worldwide [1] [2] [3] . The mechanisms of DN are not very clear, but the extensive investigation has documented the key role of the rennin angiotensin aldosterone system (RAAS) in the pathogenesis and pathophysiology of DN [4] . Accordingly, blockade of the RAAS is first-line therapy in the treatment of diabetic nephropathy [5] .
Blockade of the RAAS has been shown to reduce proteinuria and the rate of decline of glomerular filtration rate (GFR) in proteinuric nephropathies, including diabetic nephropathy.
However not all patients who are treated with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) show a clear antiproteinuric
response. An insufficient response to ACE inhibition might be explained by incomplete blockade: At least 40% of angiotensin II (AngII) is produced via other non-ACE pathways, such as chymase [6] . This incomplete blockade possibly explains the observation that plasma AngII levels return to normal after chronic ACEI treatment, a phenomenon that is known as ACE escape [7] .
Theoretically, treatment with ARB may result in more complete blockade of the unfavorable actions of AngII mediated through AT1 receptors. Until recently, AT1 was considered responsible for most of the actions of AngII: secretion of aldosterone, vasoconstriction, and renal sodium reabsorption. Furthermore, AT1 plays a pivotal role in the pathophysiologic effects of AngII, such as profibrogenic and growth actions. This receptor clearly is the predominant subtype in the adult kidney and is localized in glomeruli and renal tubules. Conversely, AT2 had no or only a marginal role in renal pathology, particularly in adulthood. However, several recent studies demonstrated the presence of the AT2 in adult kidney [8] , with a range of effects related to kidney disease: regulation of the chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) and the matrix protein osteopontin, mediation of the effects of kinin system on vascular cells, nitric oxide release, and prostaglandin E2 production. Esteban et al. (2004) [9] clearly showed that only combined therapy with AT1 plus AT2 antagonists blocked renal monocyte infiltration, NF-B activation, and upregulation of related proinflammatory genes, showing than the blockade of AT2 is necessary to abolish completely the inflammatory process.
The combination of ACE inhibitors with ARBs could lead to a more effective inhibition of RAAS. Specifically, at the time when the ACE inhibitor dissociates from the ACE active site and angiotensin II concentration increases, the concurrent administration of an ARB will protect AT1 receptors from the effects of angiotensin II. Furthermore, when the ARB dissociates from the AT1, the concurrent administration of an ACE inhibitor will reduce the amount of angiotensin II available to compete with the ARB [10] . Combined RAS blockade may also prevent the ACE escape phenomenon that decreases the effectiveness of ACE inhibitors as ARBs block all angiotensin II action at the AT1 receptor sites. Indeed, evidence suggests that ACE escape occurs in patients with severe congestive heart failure (CHF). Plasma levels of angiotensin II may rise above initial values during long-term ACE inhibition, and the effects of ACE inhibitors on cardiac remodeling and lowering of sympathetic nervous system activity attenuate after 1 year of treatment [11] . Therefore, treatment with both ACE inhibitors and ARB may offer synergistic blockade of the RAAS that is not attainable with either drug alone The present study was undertaken to evaluate the effects of dual RAAS blockade with ARB (candesartan) and ACE inhibitor (perindopril) on functional renal tests in streptozotocin induced diabetic nephropathy versus ACE inhibitor or ARB alone.
Materials and Methods

Animal model
Male and female Wistar rats (n=125), 9-11 weeks old, with initial body weights of 160-300 g were used in this investigation. Rats were fed with standard food pellets and water ad libitum, housed in cages with a 12-h light/dark cycle and temperature controlled environment (temperature of 20 ± 2ºC). Animal care and treatment were conducted in accordance with institutional guidelines that comply with national and international laws and policies.
Induction of Diabetes
Diabetes was induced by a single ip injection of STZ (Sigma-Aldrich, Chemie GmbH, Germany) at dosage of 60 mg/kg dissolved in 0.1 M citrate buffer (pH 4.5).
The presence of diabetes was confirmed 72 hours later by the measurement of the tail blood glucose level with a blood glucose monitor (AccuChek, Roche Diagnostic, Germany).
The control group received ip injection of citrate buffer alone (control nondiabetic rats). Blood samples for determination of glucose were obtained by tail bleeding. Only the rats with blood glucose levels  11 mmol/L, under fasting condition (morning blood samples) were included in the study. In order to develop diabetic nephropathy the animals were left in DM condition without any treatment during the following 4 weeks. The diabetic rats (n=100) were randomly assigned to the four experimental groups (STZ, STZ+CAN, STZ+PER and STZ+CAN+PER). To estimate the symptoms and signs of diabetic nephropathy, the STZ group of rats (n=25) was left without treatment in the following 8 weeks. For assessment of the effects of the AT1 antagonist candesartan (CAN) treatment on rats, in the STZ+CAN group of diabetic rats (n=25), candesartan was administered at dose of 5 mg/kg/per d by gavage, from week 4 to week 12. For assessment of the effects of the ACE inhibitor perindopril (PER) treatment on rats, in the STZ+PER group of diabetic rats (n=25), perindopril was administered at dose of 6 mg/kg/per d by gavage, from week 4 to week 12. For assessment of the effects of the combination of AT1 antagonist and ARB treatment on rats, in the STZ+CAN+PER group of diabetic rats (n=25), candesartan and perindopril were administered at doses of 2.5 mg/kg/per d and 3 mg/kg/per d respectively, by gavage, from week 4 to week 12.
The control group (nondiabetic rats) (n=25) received saline in the same volume and at the same time intervals as the groups of animals receiving the tested drugs.
Blood glucose
The level of blood glucose was determined before the beginning of the investigation, 72 hours after STZ application and after 4, 8 and 12 weeks of the beginning of the study.
Renal functional tests
During the study, the renal function in the examined animals was assessed by determination of serum creatinine and blood urea nitrogen (BUN) by autoanalyzer (Cobas Integra 400 Plus; Roche Diagnostics, Germany), as well as determination of the 24-hour urine volume. Urine albumin and protein in 24-hour urine samples was determined by autoanalyzer (Cobas Integra 400 Plus; Roche Diagnostics, Germany). These tests were performed prior to the beginning of the study (Day 0), and at 4, 8 and 12 weeks since the beginning of the study. In order to determine the serum levels of creatinine and BUN, blood was taken by venepuncture from the orbital sinus of the rats under light ether anaesthesia. Blood samples of 400 l were taken for serum separation (200 l).
Metabolic cages were used for collecting 24-hour urine samples for determination of urinary protein and albumin quantity as well as creatinine quantity. Creatinine clearance (CrCl) was calculated from the creatinine concentration in the collected urine sample, urine flow rate, and the plasma concentration of creatinine.
Body weight
The body weight of the examined animals was measured during the whole study in weekly intervals.
Statistics
All data were expressed as mean  SD. To test more than two groups, Kruskal-Wallis variance analysis was used, followed by Mann-Whitney U-test to determine which groups were significantly different. The p-values less than 0.05 were considered as statistically significant.
Results
Body weight
Non-diabetic group of rats (Control group) showed a gradual increase in body weight during the study. In STZ-induced diabetic rats, hyperglycemia was found to be associated with significant loss of body weight compared with nondiabetic controls (Figure 1 ).
At the end of the study, after 12 weeks, the body weight in this group of animals was reduced for 14.9% (p<0.05) as compared to the basal values. Treatment with candesartan (5 mg/kg/day) or perindopril (6 mg/kg/day) only partially prevented the weight loss among diabetic rats. At the end of the study, the body weight in these groups of animals was increased for 7.5% and 4.3% respectively, compared to the basal values. Dual blockade of the RAS with candesartan (2.5 mg/kg/day) and perindopril (3 mg/kg/day) additional prevented the weight loss, and after 12 weeks the body weight in these groups of animals was increased for 19.4% compared to the basal value (Figure 1 ). The comparison of the body weight after 12 weeks between the five experimental groups revealed a significant positive effect of combination of candesartan and perindopril (STZ+CAN+PER) on the reduction of body weight (p<0.05) compared with STZ, STZ+CAN and STZ+PER groups (Table 1) . 
24-hour urine volumen
After four weeks of administration of streptozotocin, a marked and significant (p<0.05) increase in urine volume was observed in diabetic animals compared with control group of rats. These values in the STZ group were additionally increased after 8 weeks and peaked significantly after 12 weeks. Candesartan and perindopril treatments slightly reduced the urinary volume in diabetic rats. However, the beneficial effects of the candesartan and perindopril monotherapy on 24-hour urine volume were not statistical significant (p>0.05) during the study (Figure 2 ). Dual blockade of the RAS at 8, and 12 weeks, induced statistically significant (p<0.05) reduction on 24-hour urine volume compared with STZ groups of rats, and any type of monotherapy (candesartan or perindopril) ( Table 2 ). 
Serum creatinine and BUN
For assessment of the renal function in investigated rats, serum creatinine and BUN levels were used as a routine parameters.
At 4 weeks, rats with diabetes exhibited significantly higher values serum creatinine and BUN than control rats and were randomized to receive treatments.
These values in the STZ group were additionally increased after 8 weeks and peaked significantly after 12 weeks. At the end of the study, the serum concentrations of creatinine and BUN in the STZ group were increased about threefold in comparison to the control group and basal values (p<0.05).
Monotherapy with candesartan or perindopril, although significantly (p<0.05), only partially reduced the elevated levels of serum creatinine and BUN during the study. Combined administration of candesartan and perindopril further lowered elevated levels of serum creatinine and BUN after 8 and 12 weeks (Figure 3 and 4) . Comparative statistical analysis of the serum creatinine and BUN levels of the STZ+CAN and STZ+PER groups has shown similar effects without significant differences (p>0.05). However, during the study (at weeks 8 and 12), mean serum creatinine and BUN levels of rats given a combination of candesartan and perindopril were significantly lower (p<0.05) than those of diabetic rats treated with candesartan or perindopril monotherapy (Table 3) . Albuminuria and proteinuria were significantly reduced by all three types of interruption of the RAS compared with STZ group of rats. Candesartan and perindopril were equally effective. Dual blockade of the RAS induced an additional reduction in albuminuria and proteinuria compared with any type of monotherapy ( Figure 5 and 6 ). The comparison of the urine albumin and protein excretion after 8 and 12 weeks between the all three types of interruption of the RAS revealed a statistically significant positive effect of dual blockade of the RAS with candesartan and perindopril on the reduction of albuminuria and proteinuria versus monotherapy with the some drugs (p<0.05) ( Table 4) .
Creatinine clearance
Creatinine clearance was used as specific parameter to assess glomerular filtration rate (GFR). In the early weeks of diabetes (after 4 weeks of administration of STZ), there was a significant (p<0.05) increase in creatinin clearance that gradually decreased in later weeks. After 8 weeks, the creatinine clearance values in the STZ group were decreased about two fold in comparison to the control group and basal values (p<0.05). At the end of the study, after 12 weeks, there was an additional decrease of the creatinine clearance values (for 62% compared to basal values) (Figure 7 and 8 ). Treatment with candesartan or perindopril (as a monotherapy), partially prevented the decrease of creatinine clearance among diabetic rats. At the end of the study, the creatinin clearance in these groups of animals was decreased for 29.85% and 28.99% respectively, compared to the basal values. Dual blockade of the RAS additional prevented the decrease of creatinin clearance, and after 12 weeks the mean value of creatinin clearance in these groups of animals was decreased only for 18.6% compared to the basal values (Figure 7 and 8) .
The comparison of the levels of creatinine clearance during the study (at 4, 8 and 12 weeks) between the five experimental groups, revealed a significant positive effect of combination of candesartan and perindopril (STZ+CAN+PER) on the reduction of creatinine clearance (p<0.05) compared with STZ, STZ+CAN and STZ+PER groups (Table 5 ). 
Discussion
Diabetic nephropathy, classically defined by the presence of proteinuria (macroalbuminuria, or "severely increased albuminuria"), is a common problem that is most likely to occur in patients who have worse glycemic control, hypertension, glomerular hyperfiltration or a genetic predisposition [12] . The lifetime risk of nephropathy is roughly equivalent in type 1 and type 2 diabetes [13] .
The earliest clinical manifestation of renal involvement in diabetes is an increase in albumin excretion (microalbuminuria, or "moderately increased albuminuria"), a stage at which renal histology may be relatively normal or may reveal glomerulosclerosis [14] [15] [16] [17] .
For the time being there is no specific treatment for diabetic nephropathy. The best way for the treatment is prevention, in a form of early detection and treatment of microalbuminuria.
The rennin angiotensin aldosteron system (RAAS) is a key player in the progression of diabetic renal disease. Agents blocking the renin angiotensin system, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB), are preferred for preventing albuminuria and delaying progression of DN [18] .
The primary effect of ACE inhibitors is mediated through reduced generation of angiotensin II, but additional effects, perhaps mediated through bradykinin accumulation, may also contribute to the beneficial effect. ACE inhibitors are currently first-line therapy in type 1 diabetic patients with diabetic nephropathy according to the Captopril Collaborative Study [19] but the effect of ARBs has not been investigated thoroughly.
Despite maximal recommended doses of ACE inhibitors, several patients with diabetic nephropathy do not reach blood pressure target, have persistent albuminuria and rapid progression of renal disease. Insufficient response during sustained therapy may be partly related to under-dosing or the ACE-escape phenomenon, generation of angiotensin II through alternate enzyme pathways such as chymase [20] or individual factors.
Blockade of the RAAS at AT1 receptor level by ARB treatment should overcome these drawbacks, but a potential benefit from bradykinin accumulation during ACE inhibitor treatment will then be missed. Furthermore, increased plasma concentrations of angiotensin II during ARB treatment [21, 22] could be unfavorable if AT2 receptor stimulation confers adverse renal effects as suggested by Cao et al [23, 24] . Concomitant ACE inhibitor treatment reduces angiotensin II levels [22] , thus, dual blockade of the RAAS by ACE inhibition and ARBs may offer additional renoprotective effect compared to monotherapy with either agent alone.
In our study, the single i.p. administration of STZ have caused diabetes with clearly symptoms and signs of diabetic nephropathy, including poor general condition, body weight loss, as well as abnormalities of serum and urinary renal function tests. In diabetic rats, significant increased values of serum creatinine and BUN, accompanied by increased diuresis, proteinuria, albuminuria and decreased clearance of creatinine (as a measure of glomerular filtration rate) of the experimental animals have been manifested 4 weeks after, and even more distinctly 8 and 12 weeks after administering STZ.
Treatment with candesartan (5 mg/kg/day) or perindopril (6 mg/kg/day) as monotherapy, although significantly, only partially prevented the symptoms and signs of DN among diabetic rats. Candesartan and perindopril were equally effective in treatment of DN in diabetic rats.
Combination therapy with candesartan and perindopril was more effective than monotherapy with either drug in the treatment of diabetic nephropathy.
Dual RAAS blockade with candesartan and perindopril significantly decreased all symptoms and signs of DN. Diabetic rats treated with candesartan and perindopril showed a significant reduction of the values of BUN and serum creatinine, albuminuria, proteinuria, glomerular filtration rate and diuresis compared to monotherapy.
The results obtained from this study clearly demonstrate that combination treatment with low doses of both drugs is more effective than higher doses of each compound on all tested parameters.
The rationale for dual blockade of the RAS system is based on the different mechanisms of action of the two drug classes. In addition to decreased AngII formation ACE-I decrease the degradation of bradykinin, a powerful vasodilator [25] . However, an insufficient response to ACE-I might be explained by incomplete blockade of the ACE enzyme or by the generation of AngII by ACE-independent pathways such as chymase [26] . The incomplete blockade possibly explains the observation that plasma AngII levels return to normal after chronic ACE-I treatment, a phenomenon called ACE-escape [27] . Treatment with AngII receptor blockers may result in more complete blockade of the unfavorable actions of AngII mediated through the AngII type 1 receptor. However, new data from animal studies indicate that some of the deleterious effects of AngII on glomerular cell migration, tubular cell proliferation, and development of urinary protein excretion may be mediated through the AngII type 2 receptor [28] [29] [30] . Therefore, treatment with both ACE and ARB may offer synergistic blockade of the RAAS, not obtainable with either drug alone.
A recent study of combined treatment with ACE inhibition and ARB in healthy rats demonstrated that renal angiotensin II levels were lowered by monotherapy with either agent [31] in accordance with previous experimental studies of ARBs [32] . Dual blockade of the RAAS caused a further reduction of kidney angiotensin II levels, whereas separate doseescalation studies of both agents were unable to demonstrate similar degree of suppression of kidney angiotensin II levels. According to these experimental data, combined treatment with ACE inhibition and ARB may induce a supplementary effect on the intrarenal RAAS, unavailable by monotherapy with either agent.
